SCHEMBL2249251

SCHEMBL2249251

OCc1ccc(CN2CCCCC2)cc1

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.78
HRH4 Q9H3N8 1/20 0.69
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 3/20 0.67
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
MBTD1 Q05BQ5 1/20 0.59
L3MBTL3 Q96JM7 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
POLB P06746 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
NCF1 P14598 1/20 0.55
MEN1 O00255 1/20 0.55
GFER P55789 1/20 0.55
KMT2A Q03164 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31103424 0.98 HRH3 (0.75) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL2250410 0.98 HRH3 (0.74) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL20210251 0.93 HRH3 (0.67) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL28626056 0.92 HRH3 (0.77) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL4277270 0.89 HRH3 (1.00) HRH3HRH4ALDH1A1KDM4ECYP2D6
Hydrochloric Acid SCHEMBL7468055 0.86 HRH3 (0.95) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL11201497 0.86 HRH3 (0.94) HRH3HRH4ALDH1A1KDM4ECYP2D6
Hydrochloric Acid SCHEMBL11196296 0.84 HRH3 (0.90) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL1799290 0.83 HRH3 (0.72) HRH3HRH4ALDH1A1KDM4ECYP2D6
SCHEMBL1888525 0.83 HRH3 (0.78) HRH3HRH4ALDH1A1KDM4ECYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS AG (CH) 2024-07-25 US disclosed
EP-4289838-A2 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2023-12-13 EP disclosed
US-11827612-B2 Hydroxamic acid derivative, method for producing same and use thereof INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-11-28 US disclosed
US-11827612-B2 Hydroxamic acid derivative, method for producing same and use thereof INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-11-28 US disclosed
EP-3599236-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2023-08-23 EP disclosed
US-20220411402-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2022-12-29 US disclosed
US-11414399-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2022-08-16 US disclosed
US-20220033369-A1 HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-02-03 US disclosed
CN-113454086-A Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2021-09-28 CN disclosed
US-11117898-B2 Pyrazolo-heteroaryl derivative, preparation method and medical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-09-14 US disclosed
US-20110281844-A1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS SCHWARTZ JEAN-CHARLES (FR) 2011-11-17 US disclosed
WO-2011100380-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2011-08-18 WO disclosed
US-20110196150-A1 Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same CELGENE CORPORATION 2011-08-11 US disclosed
US-7910605-B2 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications SOCIETE CIVILE BIOPROJET (FR) 2011-03-22 US disclosed
US-7910605-B2 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications SOCIETE CIVILE BIOPROJET (FR) 2011-03-22 US disclosed
WO-2010065782-A1 METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS INSPIRE PHARMACEUTICALS, INC. (US) 2010-06-10 WO disclosed
WO-2009155209-A1 OPHTHALMIC FORMULATION OF RHO KINASE INHIBITOR COMPOUND INSPIRE PHARMACEUTICALS, INC. (US) 2009-12-23 WO disclosed
EP-2000462-A2 Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications BIOPROJET (FR) 2008-12-10 EP disclosed
US-7169928-B2 central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants SOCIETE CIVILE BIOPROJECT (FR) 2007-01-30 US disclosed
US-7169928-B2 central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants SOCIETE CIVILE BIOPROJECT (FR) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 HRH3 4782/4885HRH4 4184/4885ALDH1A1 2942/4885
US-11117898-B2 Pyrazolo-heteroaryl derivative, preparation method and medical use thereof TLR7, TLR3, TLR4 HRH3 157/4885HRH4 94/4885ALDH1A1 1071/4885
US-20110196150-A1 Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same CYP3A7, CYP3A4, CYP3A43 HRH3 1764/4885HRH4 1188/4885ALDH1A1 1096/4885
US-20220411402-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 HRH3 1764/4885HRH4 1188/4885ALDH1A1 1096/4885
US-20220033369-A1 HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF HACL2, NAAA, LCT HRH3 1787/4885HRH4 1791/4885ALDH1A1 2190/4885
US-11414399-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CYP3A7, CYP3A4, CYP3A43 HRH3 1764/4885HRH4 1188/4885ALDH1A1 1096/4885
US-20110281844-A1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS HRH3, HRH4, HRH2 HRH3 1/4885HRH4 2/4885ALDH1A1 3068/4885
US-11827612-B2 Hydroxamic acid derivative, method for producing same and use thereof HACL2, NAAA, LCT HRH3 1787/4885HRH4 1791/4885ALDH1A1 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.